Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Research

NJEDA to Make Additional Lab Space Available for State’s Growing Biotechnology Companies

Trenton, NJ, August 21, 2017 — The New Jersey Economic Development Authority (EDA) on August 17 announced it will again expand its successful incubator program with the creation of the Biotechnology Development Center (BDC) on the 50-acre Technology Centre of New Jersey research park in North Brunswick.

The BDC will offer suites of intermediate lab and office space from 3,400 to 10,000 square feet for emerging life sciences companies including those that have outgrown incubator space and other early stage companies looking to expand. More than 32,600 square feet of new space is now available at the BDC. Continue reading

Event: Online Registration Open! HINJ to Host 2017 Life Sciences Celebration on October 12 in Trenton

New Brunswick, NJ, August 18, 2017 ― The HealthCare Institute of New Jersey (HINJ) will honor meritorious leadership in and contributions to New Jersey’s life sciences community at HINJ’s Life Sciences Celebration 2017, which will be held Thursday, October 12 from 8:00 to 10:00 a.m. at the Historic Trenton Masonic Temple, 100 Barrack Street, Trenton.

Online registration for the free event is now open.

HINJ’s 2017 honorees are: Continue reading

Rutgers Cancer Institute Reports Favorable Safety Profile Seen in Immunotherapy Drug in Aggressive Form of Lung Cancer

Dr. Janice M. Mehnert

New Brunswick, NJ, August 18, 2017 — The immunotherapy drug pembrolizumab has demonstrated a favorable safety profile and “promising durable clinical activity” in pretreated patients who exhibit high levels of the PD-L1 protein in advanced stages of small cell lung cancer (SCLC) – an aggressive form of the disease.

That is according to data from a phase 1b clinical trial conducted by Rutgers Cancer Institute of New Jersey investigators and colleagues at centers around the world. The work appears in the current online edition of the Journal of Clinical Oncology (doi: 10.1200/JCO.2017.72.5069).

Janice M. Mehnert, MD, director of the Phase 1/Investigational Therapeutics Program at Rutgers Cancer Institute, and senior director on the work said, “Immunotherapy drugs put the body’s natural defenses bak to work by targeting the PD-L1 protein and PD-1 receptor and blocking their ability to prevent T cells from destroying cancer cells.” Continue reading

Opinion: Assemblymen and Stevens President Urge ‘Restore Funding to Turbocharge NJ’s Research and Development’

Trenton, NJ, August 16, 2017Assemblyman Raj Mukherji (D-Hudson), Assemblyman Troy Singleton (D-Burlington) and Dr. Nariman Farvardin, president of Stevens Institute of Technology, write on innovation and Assembly No. 5123 in an op-ed published on August 15 in The Star-Ledger:

One need only to look at the top performers in the S&P 500 — Amazon, Apple, Google parent Alphabet and Facebook — to confirm an indisputable fact about our modern economy: Technological innovation is the key driver of economic growth.

Policymakers who ignore technology’s disruptive impact on markets, industries and jobs do so at their constituents’ peril. (Think Amazon’s impact on the retail industry.) Continue reading

Rutgers New Jersey Medical School Scientists Study How Worm Infections Can Weaken Immune Systems — And Life-Saving Vaccinations

New Brunswick, NJ, August 9, 2017 — Why are malaria, tuberculosis and hepatitis so prevalent in developing nations?  And why are most vaccines against these pathogens so ineffective?

Two Rutgers New Jersey Medical School scientists believe they may have found an answer in parasitic intestinal worms — which infect more than 1.5 billion people worldwide and can weaken the immune system’s ability to fend off disease, rendering vaccines less effective.

George Yap and William Gause received a $3 million grant from the National Institutes of Health this spring to study how worms prevent vaccinations from bolstering the immune system. Continue reading

U.S. Senate Passes Bill to Improve Cancer Drugs for Children

Washington, DC, August 7, 2017 — Ledyard King reports in USA Today that, until now, drug companies have been free to decide whether to pursue treatments for pediatric cancers as part of their work on adult cancers.

They won’t have much choice going forward.

The Senate on August 3 overwhelmingly passed legislation requiring the pharmaceutical industry to expend more resources on treatment for childhood cancers. Continue reading

California Received Largest NIH Awards Between 2007-2016; New Jersey Award Funding Decreased

Bethesda, MD, August 5, 2017 — The State Science & Technology Institute (SSTI) news blog reports that, with a focus on improving health, driving economic growth, and expanding the country’s research capacity, the National Institutes of Health (NIH) is the largest public funder of biomedical research in the world.

Because of NIH’s central role in supporting science, technology, and innovation, a better understanding of the agency’s footprint may be helpful to the technology-based economic development practitioner community.

This edition of Useful Stats utilizes data from NIH’s Research Portfolio Online Reporting Tool (RePORT) and covers each year from 2007 to 2016. The data does not include projects funded by the American Recovery and Reinvestment Act of 2009. Continue reading

EVENT: Save the Date! HINJ to Host 2017 Life Sciences Celebration on October 12 in Trenton

New Brunswick, NJ, July 31, 2017 ― Please mark your calendar to join the HealthCare Institute of New Jersey (HINJ) in honoring meritorious leadership in and contributions to New Jersey’s life sciences community at HINJ’s Life Sciences Celebration 2017, which will be held Thursday, October 12 from 8:00 to 10:00 a.m. at the Historic Trenton Masonic Temple. 100 Barrack Street, Trenton.

HINJ’s 2017 honorees are: Continue reading

RWJBarnabas Health and Rutgers Announce Partnership Creating New Jersey’s Premier Academic Health Care System

New Brunswick, NJ, July 28, 2017 — RWJBarnabas Health and Rutgers University yesterday announced plans to partner and create the state’s largest academic health care system dedicated to providing high-quality patient care, leading-edge research and world-class health and medical education that will transform and advance health care in New Jersey.

Rutgers University President Robert Barchi, RWJBarnabas Health President and CEO Barry H. Ostrowsky and Rutgers Biomedical and Health Sciences Chancellor Brian Strom provided details of the new partnership outlined in a formal Letter of Intent during a ceremony at the Rutgers Cancer Institute of New Jersey in New Brunswick. Continue reading

PhRMA Publishes 2017 Biopharmaceutical Industry Resources; Member Companies Spent $65.5 Billion on R&D in 2016

PhRMA’s 2017 “Chart Pack”

Washington, DC, July 28, 2017 — Did you know that Pharmaceutical Research and Manufacturers of America (PhRMA) member companies invested $65.5 billion in research and development (R&D) in 2016?

Or that combined spending on brand medicines, generics and the supply chain account for 14 percent of total national health spending, with brands accounting for just half of this (7 percent)?

Or that the United States accounts for two thirds of the world’s venture capital investments in high-growth biopharmaceutical startups?

These are but a few of the facts that can be found in PhRMA’s 2017 Biopharmaceutical Research Industry Profile and the 152-page industry chart pack, Biopharmaceuticals in Perspective, which were released July 20.
Continue reading